Kymera Therapeutics (KYMR) Financial Analysis & Valuation | Quarter Chart

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in ... more
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel ... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$9.10BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEONello Mainolfi
IPO Date2020-08-21CAGR
Employees253Websitewww.kymeratx.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
KYMR chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$10.61BP/E-31.32Forward P/E-25.39PEG
P/S228766.95P/B9081.54P/CF-57533.44P/FCF-48263.52
Sales$51.47MSales 1Y-12.6%Sales 3Y10.27%Sales 5Y4.37%
EPS$-3.53EPS 1YEPS 3YEPS 5Y
Sales QoQ1101.57%EPS QoQ-27.55%Sales QoQ Avg245.26%EPS QoQ Avg-2.12%
Gross Margin100%Operating Margin-697.81%Profit Margin-612.17%ROCE-22.36%
ROA-19%ROE-25%Altman Z Score40.83Piotroski Score2
Current Ratio10.81Quick Ratio10.81Cash Ratio2.3Op. CF Ratio-1.42
Debt/Equity0.05Debt/Assets0.05Lt Debt/Equity0.04Lt Debt/Cap.
Intrst Cov.-1508.94Inventory TurnoverAsset Turnover0.03Receivables Turnover
Enterprise Value$10.61BP/E Ratio-31.32
Forward P/E-25.39PEG Ratio
P/S Ratio228766.95P/B Ratio9081.54
P/CF Ratio-57533.44P/FCF Ratio-48263.52
EPS$-3.53EPS Growth 1Y
EPS Growth 3YEPS Growth 5Y
Revenue Growth 1Y-12.6%Gross Margin1%
Operating Margin-6.98%Profit Margin-6.12%
ROE-0.25%ROA-0.19%
ROCE-0.22%Current Ratio10.81
Quick Ratio10.81Cash Ratio2.3
Debt/Equity0.05Interest Coverage-1508.94
Altman Z Score40.83Piotroski Score2

Kymera Therapeutics (KYMR) valuation & financials

Kymera Therapeutics (KYMR) has a market capitalization of $9.10B and trades at a price-to-earnings ratio of -31.3. It operates in the Healthcare sector (Biotechnology).

Kymera Therapeutics's revenue grew -12.6% over the last year.

Kymera Therapeutics's next earnings report is scheduled for August 10, 2026 before market open; analysts estimate EPS of $-0.72.

📈 Analysts estimate KYMR EPS of $-0.72 for the upcoming quarter. See Kymera Therapeutics revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Kymera Therapeutics (KYMR) — frequently asked questions

When does Kymera Therapeutics (KYMR) report earnings next?

Kymera Therapeutics is expected to report earnings on August 10, 2026 before market open. Analysts estimate EPS of $-0.72.

What is Kymera Therapeutics's market cap?

Kymera Therapeutics (KYMR) has a market capitalization of $9.10B.

What is KYMR's P/E ratio?

Kymera Therapeutics trades at a price-to-earnings ratio of -31.3, with trailing twelve-month EPS of $-3.53.

How fast is Kymera Therapeutics growing?

Kymera Therapeutics's revenue grew -12.6% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)